Literature DB >> 27939091

Understanding the acute inflammatory response to Pseudomonas aeruginosa infection: differences between susceptible and multidrug-resistant strains in a mouse peritonitis model.

Silvia Gómez-Zorrilla1, Laura Calatayud2, Carlos Juan3, Gabriel Cabot3, Fe Tubau2, Antonio Oliver3, Maria Angeles Dominguez2, Javier Ariza1, Carmen Peña4.   

Abstract

The increasing emergence of multidrug-resistant (MDR) Pseudomonas aeruginosa strains is associated with the spread of a few international epidemic clones called high-risk clones. The existence of a fitness cost associated with multidrug resistance remains unclear, and little is known about the host inflammatory response in acute P. aeruginosa infections. This study aimed to investigate how the inflammatory response occurs in the most relevant high-risk clones and to compare the process with that recorded in clinical susceptible isolates. Nine P. aeruginosa strains were studied, including the most relevant MDR high-risk clones (ST111, ST175 and ST235) circulating worldwide. The inflammatory response in terms of the release of interleukins in serum was investigated in a mouse peritonitis-sepsis model at three time points (4, 8 and 12 h). TNFα and interleukin-10 (IL-10) levels were significantly higher at all time points in mice inoculated with clinical susceptible strains compared with those inoculated with MDR strains. IL-6 levels were significantly higher in the clinical susceptible strain group at 8 h and 12 h (P = 0.036 and P = 0.007, respectively). Bacterial counts (log CFU/mL) in peritoneal fluid were higher in the clinical susceptible strain group compared with the MDR strain group at 8 h [6.00 (4.30-6.90) vs. 4.46 (3.30-5.34); P = 0.005] and 12 h [7.75 (4.00-7.97) vs. 4.04 (2.58-4.94); P = 0.003]. MDR P. aeruginosa strains elicited a weaker inflammatory response than susceptible strains in an experimental mouse model, suggesting the existence of a fitness cost associated with multidrug resistance.
Copyright © 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Animal model; Antibiotic resistance; High-risk clone; Interleukin-10; Interleukin-6; Tumour necrosis factor-alpha

Mesh:

Substances:

Year:  2016        PMID: 27939091     DOI: 10.1016/j.ijantimicag.2016.10.016

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

1.  Evaluation of Platensimycin and Platensimycin-Inspired Thioether Analogues against Methicillin-Resistant Staphylococcus aureus in Topical and Systemic Infection Mouse Models.

Authors:  Meng Su; Lin Qiu; Youchao Deng; Claudia H Ruiz; Jeffrey D Rudolf; Liao-Bin Dong; Xueqiong Feng; Michael D Cameron; Ben Shen; Yanwen Duan; Yong Huang
Journal:  Mol Pharm       Date:  2019-06-19       Impact factor: 4.939

2.  Multidrug-Resistant Pseudomonas aeruginosa Evokes Differential Inflammatory Responses in Human Microglial and Retinal Pigment Epithelial Cells.

Authors:  Poonam Naik; Sukhvinder Singh; Sushma Vishwakarma; Inderjeet Kaur; Vivek Pravin Dave; Ashok Kumar; Joveeta Joseph
Journal:  Microorganisms       Date:  2020-05-14

3.  Multidrug-resistant organisms (MDROs) in patients with subarachnoid hemorrhage (SAH).

Authors:  Ha-Young Rhim; Sae-Yeon Won; Sepide Kashefiolasl; Nina Brawanski; Elke Hattingen; Joachim Berkefeld; Volker Seifert; Juergen Konczalla
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

Review 4.  Expanding the Current Knowledge About the Role of Interleukin-10 to Major Concerning Bacteria.

Authors:  Hernán F Peñaloza; Loreani P Noguera; Claudia A Riedel; Susan M Bueno
Journal:  Front Microbiol       Date:  2018-09-18       Impact factor: 5.640

5.  Small Molecule Inhibitor of Type Three Secretion System Belonging to a Class 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones Improves Survival and Decreases Bacterial Loads in an Airway Pseudomonas aeruginosa Infection in Mice.

Authors:  Anna B Sheremet; Naylia A Zigangirova; Egor S Zayakin; Sergei I Luyksaar; Lydia N Kapotina; Ludmila N Nesterenko; Natalie V Kobets; Alexander L Gintsburg
Journal:  Biomed Res Int       Date:  2018-09-10       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.